2 diabetes drugs up for FDA safety review in April

03/9/2009 | CNNMoney

An FDA advisory committee is scheduled next month to examine whether Bristol-Myers Squibb's saxagliptin and Novo Nordisk's liraglutide increase the risks of heart attack and stroke in patients with Type 2 diabetes. The move is in line with the agency's guidance issued in December.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC